June 2025. Volume 21. Number 2

Treatment with crinecerfont in patients with congenital adrenal hyperplasia improves the substitutive therapeutic control with corticosteroids

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Auchus RJ, Hamidi O, Pivonello R, Bancos I, Russo G, Witchel SF, et al. Phase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal Hyperplasia. N Engl J Med. 2024;391:504-14.

Reviewers: Rivero Martín MJ1, Blanco Rodríguez C2.
1Servicio de Pediatría. Hospital Universitario de Fuenlabrada. Departamento de Medicina. Universidad Rey Juan Carlos. Fuenlabrada. Madrid. España.
2Pediatra. CS Sanchinarro. Madrid. España.
Correspondence: M.ª José Rivero Martín. Email: mriverom@salud.madrid.org
Reception date: 16/04/2025
Acceptance date: 29/04/2025
Publication date: 14/05/2025

Abstract

Authors ́conclusions: treatment with crinecerfont in children with congenital adrenal hyperplasia (CAH) decreases androstenedione levels and allows a reduction in the replacement maintenance dose with glucocorticoids while maintaining good control of androstenedione levels.

Reviewers ́ commentary: this study, of adequate design and quality, concludes that crinecerfont helps improve androgen control in patients with classic CAH, with few side effects in the short term. Studies with long-term follow-up are needed to assess the effect on bone metabolism, final height and impact on quality of life.

How to cite this article

Rivero Martín MJ, Blanco Rodríguez C. El tratamiento con crinecerfont en pacientes con hiperplasia suprarrenal congénita mejora el control terapéutico sustitutivo con corticoides. Evid Pediatr. 2025;21:16.

AVC | Critically appraised articles

Auchus RJ, Hamidi O, Pivonello R, Bancos I, Russo G, Witchel SF, et al. Phase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal Hyperplasia. N Engl J Med. 2024;391:504-14.

Reviewers: Rivero Martín MJ1, Blanco Rodríguez C2.
1Servicio de Pediatría. Hospital Universitario de Fuenlabrada. Departamento de Medicina. Universidad Rey Juan Carlos. Fuenlabrada. Madrid. España.
2Pediatra. CS Sanchinarro. Madrid. España.
Correspondence: M.ª José Rivero Martín. Email: mriverom@salud.madrid.org
Reception date: 16/04/2025
Acceptance date: 29/04/2025
Publication date: 14/05/2025

How to cite this article

Rivero Martín MJ, Blanco Rodríguez C. El tratamiento con crinecerfont en pacientes con hiperplasia suprarrenal congénita mejora el control terapéutico sustitutivo con corticoides. Evid Pediatr. 2025;21:16.

14/05/2025

Linked Comment